The effect of allergen immunotherapy in patients with central compartment atopic disease post‐surgery
International Forum of Allergy & Rhinology · 2025-02 · 15 (2) · 128-134
DOI: 10.1002/alr.23459 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 27.09.2024. Verfasst von Christian M Meerwein und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Nasal Polyps, Postoperative Complications. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To assess the effect of allergen immunotherapy (AIT) on patients with central compartment atopic disease (CCAD) and house dust mite (HDM) sensitization post‐surgery.
Methods
A retrospective cohort of surgically treated, HDM‐sensitized CRSwNP patients phenotyped as CCAD was assessed. Patients were divided into two groups based on whether they had AIT commenced as part of their surgical care. All AIT patients started immunotherapy prior to their surgery. The primary endpoint was reformation of middle turbinate (MT) edema 12 months postsurgery. Secondary endpoints were corticosteroid irrigation use ( 100/HPF), and serum IgE (kU/L) were also recorded.
Results
Eighty‐six CCAD patients were assessed (41 ± 14 yrs, 64% female). AIT was applied in 37% ( n = 32). Baseline features were similar apart from greater conjunctival symptoms (72 vs. 45%, p = 0.02) in the AIT group. At 12 months post‐surgery, the AIT group has less MT edema (% ≥ diffuse 15.6 vs. 52.9, p < 0.01). Patients on AIT also had less pharmacotherapy requirements at 12 months (% ≥ 4/week, 37.5 vs. 79.6%, p < 0.01). The rhinologic symptoms were similar (21.1 ± 17.1 vs. 20.1 ± 21.6, p = 0.83).
Conclusions
Surgery and pharmacotherapy are effective in managing CCAD, but the addition of AIT improved allergic phenomenon and allowed de‐escalation of topical therapy. Longer term studies are required to demonstrate further immunomodulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, Australia.
- Department of Otorhinolaryngology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
- Department of Otolaryngology, Head and Neck Surgery, Concord General Hospital, University of Sydney, Sydney, Australia.
- Faculty of Medicine, University of Sydney, Sydney, Australia.
- Department of Otolaryngology, Head and Neck Surgery, Royal Prince Alfred Hospital, Sydney, Australia.
- Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
ORCID-Profile: Christian M Meerwein, Peta-Lee Sacks, Richard J Harvey
Zitieren
APA
Meerwein, C. M., Sacks, P. L., Ho, J., Choy, C., Kalish, L., Campbell, R. G., Sacks, R. R., & Harvey, R. J. (2025). The effect of allergen immunotherapy in patients with central compartment atopic disease post‐surgery. International Forum of Allergy & Rhinology, 15(2), 128-134. https://doi.org/10.1002/alr.23459
Vancouver
Meerwein CM, Sacks PL, Ho J, Choy C, Kalish L, Campbell RG, et al. The effect of allergen immunotherapy in patients with central compartment atopic disease post‐surgery. International Forum of Allergy & Rhinology. 2025;15(2):128-134. doi:10.1002/alr.23459
BibTeX
@article{Meerwein2025,
author = {Meerwein, Christian M and Sacks, Peta-Lee and Ho, Jacqueline and Choy, Christine and Kalish, Larry and Campbell, Raewyn G and Sacks, Ray R and Harvey, Richard J},
title = {The effect of allergen immunotherapy in patients with central compartment atopic disease post‐surgery},
journal = {International Forum of Allergy & Rhinology},
year = {2025},
volume = {15},
number = {2},
pages = {128--134},
doi = {10.1002/alr.23459}
}
EUVIMED